Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 2330811

Next Previous
Search
Drug Profile

GSK 2330811

Alternative Names: GSK-2330811

Latest Information Update: 28 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Antifibrotics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Oncostatin M inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Systemic scleroderma

Most Recent Events

  • 03 Feb 2021 Discontinued - Phase-II for Systemic scleroderma (Adjunctive treatment) in Canada, USA, Netherlands, United Kingdom (SC) (GlaxoSmithKline pipeline, February 2021)
  • 03 Dec 2020 GlaxoSmithKline terminates a phase II COSMIS trial in Crohn's disease (Treatment experienced) (SC), prior to enrolment because of internal sponsor's decision to terminate project in Crohn's disease due to potential narrow therapeutic window (NCT04151225)
  • 05 Oct 2020 Phase II development is still ongoing for Systemic scleroderma (Adjunctive treatment) in United Kingdom (NCT03041025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top